STAT3 and breast carcinoma: Thus, the research's primary aim is to examine if naringin, alone or in combination with the chemotherapeutic drug doxorubicin, could inhibit the growth and multiplication of MCF-7 breast cancer cells by suppressing the STAT3 signaling pathway.